(Q40661505)

22 September 2017

title

Use of Broncho-Vaxom in private practice: phase IV trial in 587 children (English)

1 reference

22 September 2017

main subject

phase IV clinical trial

0 references

author name string

Berber AC

series ordinal

1

1 reference

22 September 2017

Del-Rio-Navarro BE

series ordinal

2

1 reference

22 September 2017

publication date

1 November 1996

1 reference

22 September 2017

published in

Clinical Therapeutics

1 reference

22 September 2017

volume

18

1 reference

22 September 2017

issue

6

1 reference

22 September 2017

page(s)

1068-1079

1 reference

Stimulation of immunoprotective mechanisms by OM-85 BV. A review of results from in vivo and in vitro studies

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Upregulation of adhesion molecules induced by broncho-vaxom on phagocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Activation of natural killer cells and cytokine production in man by bacterial extracts

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Effects of the Bacterial Extract OM-85 on Phagocyte Functions and the Stress Response

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Influence of a bacterial extract on antigen presentation and protection against experimental infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Immunoglobulin production in man stimulated by an orally administered bacterial lysate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Broncho-Vaxom, on T lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Broncho-Vaxom in children with rhinosinusitis: a double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

[Conservative treatment of chronic sinusitis. Success of oral bacterial lysate therapy]

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicrèche Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Form of day care and respiratory infections among Finnish children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Evaluating drugs after their approval for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Review of company postmarketing surveillance studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Phase IV study and post-marketing surveillance of ofloxacin in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

Illness associated with child day care: a study of incidence and cost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980062-2

7 January 2021

10.1016/S0149-2918(96)80062-2

Identifiers

DOI

1 reference

22 September 2017

1 reference